Christine Blank
Contributing Editor Christine Blank is a freelance writer based in Florida.
Walgreens faces anti-tobacco effort ahead of annual meeting
Two organizations opposed to tobacco sales at pharmacy chains are turning their attention to Walgreens’ annual shareholder meeting on January 26.
New 340B drug rule sets drugmaker fines
Consumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.
FDA approves hemophilia A drug for children
FDA recently expanded the use of antihemophilic factor (recombinant), pegylated (Adynovate, Shire plc) for hemophilia A patients under 12 years old.
New device could be breakthrough for diabetics
FDA recently expanded approval of the G5 Mobile Continuous Glucose Monitoring System (Dexcom) to allow for replacement of fingerstick blood glucose (sugar) testing for diabetics.
Why 2016 drug approvals fell
Why 2016 drug approvals fell
While FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
FDA green lights first treatment for rare spinal disease
FDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Advanced ovarian cancer drug approved
FDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.
New diabetes combo drug available soon
A new combination drug for type 2 diabetes will available in the US in the coming months.
FDA issues warnings over anesthesia, diabetes drugs
FDA issued two important drug warnings this week: one linking certain diabetes medications to bladder cancer and another about the use of general anesthetic and sedation drugs during pregnancy.
FDA approves expansion of Avastin in ovarian cancer
FDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.

Poll

View Results